Ainos, Inc. AIMD

Company Overview

Ainos, Inc. is a healthcare technology company focused on point-of-care testing, low-dose interferon therapeutics, and artificial intelligence-enabled scent digitization technologies. The company operates primarily in the biotechnology and medical technology sectors, with activities spanning rapid diagnostics, women’s health screening, and AI-driven digital olfaction research. Ainos has emphasized the development of technologies intended to improve early disease detection and decentralized healthcare delivery, particularly through mobile and rapid testing platforms.

The company’s principal business lines include its VELDONA low-dose interferon platform and its AI Nose technology initiative, which is designed to digitize and analyze scent data using sensor systems and machine learning. Historically, Ainos evolved from a biotechnology-focused enterprise into a broader health-tech company integrating AI and sensor technologies into healthcare applications. Public disclosures indicate that the company has targeted healthcare providers, research institutions, and technology partners across Asia and North America. Its positioning centers on combining biotech assets with emerging AI-enabled diagnostic capabilities.